Euvichol Or Euvichol-Plus Market Size Reaches $ Billion In 2026: What Is Driving Growth?
Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Euvichol Or Euvichol-Plus Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
Historically, the observed growth was driven by the restricted therapeutic options for cholestasis, the rising incidence of gallstone disease, the prompt adoption of UDCA therapy, increasing understanding of primary biliary cholangitis (PBC) management, and the clinical substantiation of bile acid therapies.
Projected growth during the forecast period is driven by the escalating incidence of NAFLD, the expansion of liver disease screening initiatives, a rising demand for integrated liver therapies, enhanced access to hepatology care, and increased healthcare spending on chronic conditions.
Prominent trends anticipated during the forecast period involve the increasing embrace of UDCA-based liver treatments, their growing application in cholestatic liver disorders, the development of combination therapies for improved liver protection, a rise in the diagnosis of chronic liver diseases, and the expansion of proactive liver care programs.
Get A Free Sample Report With In-Depth Market Insights:
Euvichol Or Euvichol-Plus Market Demand Drivers Opening New Revenue Streams
An increasing occurrence of liver conditions is projected to fuel the expansion of the euvichol or euvichol-plus market in the upcoming period. These ailments encompass various health issues impacting the liver, hindering its normal operation. The elevated incidence of liver diseases stems primarily from higher obesity levels, leading to non-alcoholic fatty liver disease, and significant alcohol intake, a primary factor in alcoholic liver disease. Euvichol and Euvichol Plus serve as treatments for liver ailments, especially chronic hepatitis B, by enhancing liver cell membrane integrity, diminishing inflammation, and assisting liver function. As an illustration, data from GOV.UK, a UK government body, indicated in April 2024 that hospital admissions for liver disease climbed to 155.2 per 100,000 population by the financial year ending 2023, an increase from 150.6 per 100,000 in 2022. Consequently, the rising occurrence of liver diseases is propelling the expansion of the euvichol or euvichol-plus market.
Euvichol Or Euvichol-Plus Market Segmentation: How Does The Market Break Down By Category?
The euvichol or euvichol-plus market covered in this report is segmented –
1) By Product Type: Euvichol, Euvichol-Plus
2) By Clinical Indication: Non-Alcoholic Fatty Liver Disease (NAFLD), Liver Dysfunction, Detoxification And Liver Protection
3) By Distribution Channel: Hospitals And Clinics, Pharmacies, Public Health Campaigns
Euvichol Or Euvichol-Plus Market Trends Powering Strategic Industry Growth
A significant trend in the euvichol or euvichol-plus market involves the development of technologically advanced solutions, such as the oral cholera vaccine, designed to fulfill various critical industry requirements. Oral cholera vaccines are ingested immunizations that provide protection against cholera, a bacterial infection leading to severe diarrhea and dehydration. For example, in May 2023, Techinvention Lifecare Pvt. Ltd., an India-based biotechnology company, launched Euvichol-Plus, marking it as the first oral cholera vaccine to be packaged in a low-density polyethylene (LDPE) unidose pack. This innovative packaging improves both usability and safety by reducing the risks of breakage and waste often associated with traditional glass vials. Having received approval from the Central Drugs Standard Control Organization (CDSCO) after a successful phase III clinical trial, Euvichol-Plus addresses a crucial public health need in India, where approximately 400 million people are at risk of cholera. The vaccine is projected to enhance distribution during emergencies and humanitarian crises, contributing to global efforts to eradicate cholera by 2030.
Euvichol Or Euvichol-Plus Market Competitive Overview And Top Companies
Major companies operating in the euvichol or euvichol-plus market are Eubiologics Co. Ltd., Techinvention Lifecare Pvt. Ltd.
View The Full Euvichol Or Euvichol-Plus Market Report:
Euvichol Or Euvichol-Plus Market Geographic Landscape: Which Region Leads Industry Growth?
North America was the largest region in the euvichol or euvichol-plus market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the euvichol or euvichol-plus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
